What is Inne?
Inne specializes in hormone-free contraception and fertility monitoring through its proprietary CE-certified Minilab. By utilizing saliva-based progesterone tracking, the platform provides users with precise, personalized hormone insights, effectively bridging the gap between clinical-grade diagnostics and home-based health management. With a reported 92% effectiveness rate, the company addresses a critical demand among health-conscious individuals for reliable, non-invasive alternatives to traditional hormonal birth control. Inne operates at the intersection of biotechnology and consumer electronics, aiming to empower women with actionable data to make informed reproductive choices.
How much funding has Inne raised?
Inne has raised a total of $18.8M across 1 funding round:
Series A
$18.8M
Series A (2019): $18.8M with participation from Monkfish Equity, DSM Venturing, Taavet Hinrikus, Calm/Storm Ventures, Tom Stafford, Blossom Capital, Borski Fund, and Rolf Schromgens
Key Investors in Inne
Monkfish Equity
Monkfish Equity is an investment firm that supports early-stage European startups by providing seed and growth capital, leveraging the deep entrepreneurial experience of its founders to assist in business scaling.
Calm/Storm Ventures
Calm/Storm Ventures is a boutique venture capital firm and exclusive founder network based in Vienna, focusing on early-stage investments in purpose-driven HealthTech companies across Europe and the US.
Blossom Capital
Blossom Capital is a London-based VC fund that connects US expertise and networks with European startups, focusing on high-growth consumer and enterprise companies.
What's next for Inne?
With the recent capital injection, Inne is poised to transition from its current scaling phase into a broader enterprise-level market presence. The strategic focus will likely center on enhancing the Minilab's technological infrastructure, expanding its user base across international markets, and deepening its clinical validation efforts. As the FemTech industry continues to attract significant venture interest, Inne's ability to maintain its competitive edge will depend on its capacity to integrate its data-driven insights into wider healthcare ecosystems. The company remains committed to its core mission of providing scientifically-backed, user-centric reproductive health tools that challenge the status quo of traditional contraceptive methods.
See full Inne company page
